BioArctic Sweden

New data from LEQEMBI® phase 3 Clarity AD study and subcutaneous formulation presented at CTAD

New data from LEQEMBI® (lecanemab-irmb) phase 3 Clarity AD study and subcutaneous formulation presented at CTAD

View original content:https://www.prnewswire.co.uk/news-releases/new-data-from-leqembi-lecanemab-irmb-phase-3-clarity-ad-study-and-subcutaneous-formulation-presented-at-ctad-301968090.html